Our results indicate that PRL2 plays a crucial role in suppressing FcεRI-mediated MC activation and allergic disease, suggesting that targeting PRL2 could represent a promising therapeutic strategy for treating allergies. This evidence concerns the gene PTP4A2 and Allergy.